HOME >> MEDICINE >> NEWS
Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR

Philadelphia, PA., May 19, 2003 Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that a landmark analysis of studies comparing antidepressant treatments demonstrated that significantly more patients achieved remission (virtual elimination) of their depression symptoms, and resolution of both emotional and physical symptoms, when treated with EFFEXOR/EFFEXOR XR (venlafaxine HCl) than with commonly used selective serotonin reuptake inhibitors (SSRIs) or placebo. The analysis was presented in two poster presentations at the American Psychiatric Association's (APA) annual meeting in San Francisco.

The analysis compared EFFEXOR®/EFFEXOR XR to the SSRIs PAXIL® (paroxetine), PROZAC® (fluoxetine), ZOLOFT® (sertraline), LUVOX® (fluvoxamine), and CELEXA (citalopram) and comprised the entire worldwide dataset of Wyeth-sponsored registration and post-marketing, published and unpublished, SSRI-controlled clinical studies of EFFEXOR/EFFEXOR XR to date.

"Given the urgency to treat a patient to remission, these data reinforce EFFEXOR XR as a first-line therapy for depression," says Dr. Eric Hollander, Professor of Psychiatry and Director of Psychopharmacology at Mount Sinai School of Medicine in New York City. "This is important information for physicians as remission is a critical milestone in preventing symptom recurrence and depression relapse."

In one poster it was determined that EFFEXOR/EFFEXOR XR-treated patients had significantly higher remission rates than those treated with the studied SSRIs using standard evaluations including scoring seven or less on the 17-item Hamilton Rating Scale for Depression (HAM-D17) and less than 10 on the Montgomery-Asberg Depression Rating Scale (MADRS).

Specifically, the HAM-D17 evaluation revealed a 41 percent remission rate for EFFEXOR/EFFEXOR XR patients, significantly greater than that of patients receiving an SSRI (35 percent, p<0.001), or a placebo (25 percent,
'"/>

Contact: Douglas Petkus, Wyeth Pharmaceuticals
484-865-5140
Porter Novelli
19-May-2003


Page: 1 2 3 4

Related medicine news :

1. Landmark survey reveals asthma in children remains significantly out of control in the United States
2. Landmark study shows coenzyme Q10 slows progressive decline in Parkinsons disease
3. Landmark XENDOS study shows Xenical prevents or delays the development of type 2 diabetes
4. Landmark study demonstrates potential for nerve regeneration treatment of stroke
5. Landmark study results published in NEJM highlight breakthrough treatment for heart failure
6. Landmark study uncovers reasons behind recurring back injury
7. Landmark clinical trial at 22 medical centers finds implanted heart pumps lengthen and improve lives of terminally ill heart failure patients
8. Landmark dialysis study findings could greatly simplify treatment of kidney disease with peritoneal dialysis
9. Landmark school-based social influences smoking-prevention program found not to work
10. U.S., British scientific societies honor penicillin as International Chemical Landmark
11. CODE-2*: Landmark study on the costs of type 2 diabetes in Europe

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/12/2020)... ... January 12, 2020 , ... Cecelia Health ( ... City, has continually innovated for over a decade to transform lives and health ... companies and self-insured employers. By optimizing the mix of expert clinician and digital ...
(Date:1/10/2020)... ... January 10, 2020 , ... WellHaven Pet Health, a family of ... new online community coming in February 2020, LEAD WELL with WOMEN. The community will ... , The vision of LEAD WELL with WOMEN is to empower women, engage all, ...
(Date:1/10/2020)... ... January 10, 2020 , ... ... Oregon, provides a friendly, non-intimidating environment for all women. In search for a ... its current and prospective members. , For nearly 30 years, Balanced Habits, ...
(Date:1/8/2020)... ... January 08, 2020 , ... Mirror ... Magazine’s 2019 Best of Memorial Readers’ Choice Awards. Located adjacent to ... named Best MedSpa in Memorial reflects Mirror Mirror Beauty Boutique’s commitment to the ...
(Date:1/7/2020)... ... January 07, 2020 , ... G-CON Manufacturing, the leader ... company’s 200,000 sq. ft. manufacturing site in College Station, TX. The new facility, ... POD architectural, mechanical, electrical and automation fit out. , “This facility allows us ...
Breaking Medicine News(10 mins):
(Date:1/7/2020)... ... January 07, 2020 , ... Ironsphere, a ... providers, announced today it has been selected by MetLife Stadium for Privileged Access ... “As part of our ongoing commitment to maintain the highest of security policies, ...
(Date:1/5/2020)... ... January 04, 2020 , ... The ... and software firms are fighting for leadership in both devices and voice assistant ... research report, during the past few years, multiple health-related voice assistants have been ...
(Date:1/3/2020)... ... ... Stay on top of current hot topics through free webinars presented by leading experts ... so be sure to register today to save your place. Participate in the discussion ... upcoming webinars: , CLINICAL OPERATIONS , January 23 – The Benefits of a Seamless ...
Breaking Medicine Technology:
Cached News: